Edwards' US TAVR sales fall as COVID-19 disrupts referrals

U.S. sales of Edwards Lifesciences’ transcatheter aortic valve replacement fell by mid-single digits in the fourth quarter due to COVID-19-related disruption at large treatment centers.

Edwards warned investors COVID-19 would affect fourth quarter sales at its analyst day late last year but the hit was worse than forecast. Analysts expected U.S. TAVR sales to be flat in the quarter.